Journal Article

Comparison of anti-inflammatory effects and high-density lipoprotein cholesterol levels between therapy with quadruple-dose rosuvastatin and rosuvastatin combined with ezetimibe

Yamazaki, Daisuke, Iino, Kenji, Watanabe, Hiroyuki, Terata, Yutaka, Oguma, Yasunori, Kosaka, Toshimitsu, Nobori, Kiyoshi, Ito, Hiroshi, Koyama, Takashi, Ishida, Masaru

2013

Overview

Background Statins are frequently administered to reduce low-density lipoprotein cholesterol (LDL-C) and vascular inflammation, because LDL-C and high sensitive C-reactive protein (hs-CRP) are associated with high risk for cardiovascular events. When statins do not reduce LDL-C to desired levels in high-risk patients with coronary artery disease (CAD), ezetimibe can be added or the statin dose can be increased. However, which strategy is more effective for treating patients with CAD has not been established. The present study compares anti-inflammatory effects and lipid profiles in patients with CAD and similar LDL-C levels who were treated by increasing the statin dose or by adding ezetimibe to the original rosuvastatin dose to determine the optimal treatment for such patients. Methods 46 patients with high-risk CAD and LDL-C and hs-CRP levels of >70 mg/dL and >1.0 mg/L, respectively, that were not improved by 4 weeks of rosuvastatin (2.5 mg/day) were randomly assigned to receive 10 mg (R10, n = 24) of rosuvastatin or 2.5 mg/day of rosuvastatin combined with 10 mg/day of ezetimibe (R2.5/E10, n = 22) for 12 weeks. The primary endpoint was a change in hs-CRP. Results Baseline characteristics did not significantly differ between the groups. At 12 weeks, LDL-C and inflammatory markers (hs-CRP, interleukin-6, tumour necrosis factor-alpha and pentraxin 3) also did not significantly differ between the two groups (LDL-C: R10 vs. R2.5/E10: -19.4 ± 14.2 vs. -22.4 ± 14.3 mg/dL). However, high-density lipoprotein cholesterol (HDL-C) was significantly improved in the R10, compared with R2.5/E10 group (4.6 ± 5.9 vs. 0.0 ± 6.7 mg/dL; p < 0.05). Conclusion Both enhanced therapies exerted similar anti-inflammatory effects under an equal LDL-C reduction in patients with high-risk CAD despite 2.5 mg/day of rosuvastatin. However, R10 elevated HDL-C more effectively than R2.5/E10. Trial registration UMIN000003746

• Publisher: BioMed Central,BioMed Central Ltd,Springer Nature B.V
• Subject: Adult / Aged / Aged, 80 and over / Anticholesteremic Agents - pharmacology / Anticholesteremic Agents - therapeutic use / Azetidines - pharmacology / Azetidines - therapeutic use / Biomedical and Life Sciences / C-reactive protein / C-Reactive Protein - metabolism / Cardiac patients / Cardiovascular disease / Care and treatment / Cholesterol / Cholesterol, HDL / Cholesterol, HDL - blood / Cholesterol, LDL / Cholesterol, LDL - blood / Clinical Nutrition / Comparative analysis / Coronary Disease - drug therapy / Coronary Disease - metabolism / Coronary heart disease / Drug Administration Schedule / Drug Combinations / Drugs / Ezetimibe / Female / Fluorobenzenes - pharmacology / Fluorobenzenes - therapeutic use / Health aspects / Heart attacks / Humans / Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology / Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use / Inflammation / Inflammation - drug therapy / Inflammation - metabolism / Interleukin-6 - blood / Interleukins / Life Sciences / Lipidology / Low density lipoproteins / Male / Medical Biochemistry / Middle Aged / Patient outcomes / Prospective Studies / Proteins / Pyrimidines - pharmacology / Pyrimidines - therapeutic use / Risk factors / Rosuvastatin / Rosuvastatin Calcium / Serum Amyloid P-Component - metabolism / Statins / Sulfonamides - pharmacology / Sulfonamides - therapeutic use / Tumor Necrosis Factor-alpha - blood